The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas

To investigate the prognostic impact of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement for the overall survival (OS) of patients with surgically treated lung adenocarcinomas.

[1]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[3]  Sang Min Lee,et al.  Correlation between the Size of the Solid Component on Thin-Section CT and the Invasive Component on Pathology in Small Lung Adenocarcinomas Manifesting as Ground-Glass Nodules , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Nikolaus Schultz,et al.  Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers , 2018, Clinical Cancer Research.

[5]  Chih-Wei Wang,et al.  Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma , 2017, PloS one.

[6]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[7]  Min Hwan Kim,et al.  Clinical and Prognostic Implications of ALK and ROS 1 Rearrangements in Never-Smokers with Surgically Resected Lung Adenocarcinoma , 2013 .

[8]  Hoguen Kim,et al.  Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma , 2009, Journal of Cancer Research and Clinical Oncology.

[9]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  C. Kang,et al.  The prognostic effect of the epidermal growth factor receptor gene mutation on recurrence dynamics of lung adenocarcinoma , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  N. Normanno,et al.  Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. , 2018, Translational lung cancer research.

[12]  L. Sequist,et al.  The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. , 2013, The Annals of thoracic surgery.

[13]  M. Sonobe,et al.  Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas , 2012, Annals of Surgical Oncology.

[14]  Xianhe Xie,et al.  Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. , 2017, Lung cancer.

[15]  Y. Shim,et al.  Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma. , 2018, Journal of thoracic disease.

[16]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Kang,et al.  The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Jing Zhao,et al.  Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis , 2018, Cancer management and research.

[20]  J. Chen,et al.  Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis , 2014, PloS one.

[21]  Y. Bang,et al.  Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Akihiko Yoshizawa,et al.  A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors , 2010, The American journal of surgical pathology.

[23]  Takayuki Kosaka,et al.  Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  M. Tamburini,et al.  Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. , 1996, European journal of cancer.

[25]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  M. Masuda,et al.  Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma , 2015, Medicine.

[27]  Q. Li,et al.  Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy , 2018, Clinical and Translational Oncology.

[28]  Ping Wang,et al.  Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas , 2013, Medical Oncology.

[29]  C. Kang,et al.  Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas. , 2018, Lung cancer.

[30]  C. Kang,et al.  Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[31]  S. Hahn,et al.  Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. , 2008, Lung cancer.

[32]  Yuki Matsumura,et al.  Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  C. Lee,et al.  Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. , 2012, Lung cancer.

[34]  Dong-Wan Kim,et al.  Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer , 2013, International Journal of Clinical Oncology.

[35]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[36]  Y. Yatabe,et al.  Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. , 2016, Japanese journal of clinical oncology.

[37]  Zoe Wainer,et al.  Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Qun Wang,et al.  Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  H. Lee,et al.  Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study. , 2018, Lung cancer.

[40]  David R. Jones,et al.  Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. , 2018, Lung cancer.